Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Gilead Sciences (IT:1GILD)
:1GILD
Holding IT:1GILD?
Track your performance easily
1GILD Stock Chart & Stats
Day’s Range― - ―
52-Week Range€57.73 - €92.68
Previous CloseN/A
Volume70.00
Average Volume (3M)187.00
Market Cap
$109.29B
Enterprise Value€121.60B
Total Cash (Recent Filing)$25.51B
Total Debt (Recent Filing)$30.80B
Price to Earnings (P/E)972.2
Beta0.12
Next Earnings
Feb 11, 2025EPS Estimate
1.66Next Dividend Ex-DateN/A
Dividend Yield3.43%
Share Statistics
EPS (TTM)0.09
Shares Outstanding1,246,265,900
10 Day Avg. Volume131
30 Day Avg. Volume187
Standard DeviationN/A
R-SquaredN/A
AlphaN/A
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)3.96
Price to Cash Flow (P/CF)6.50
P/FCF Ratio6.70
Enterprise Value/Market Cap1.11
Enterprise Value/Revenue4.30
Enterprise Value/Gross Profit5.90
Enterprise Value/Ebitda35.31
Forecast
1Y Price Target
€96.88Price Target Upside9.24% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering26
Gilead Sciences News
Bulls Say, Bears Say
Bulls Say
Market ExpansionThe US PrEP market could expand significantly, with the potential to reach over 1 million consumers by the mid-2030s, offering a growth opportunity for Gilead Sciences.
Product PipelinePositive pipeline developments for Lenacapavir in HIV prevention and anito-cel in multiple myeloma suggest potential for upward estimate revisions and further growth.
ValuationShares of Gilead Sciences are trading at a lower P/E ratio compared to the biopharma peer group average, indicating potential undervaluation.
Bears Say
Competitive PressuresThe cell therapy business faced competitive pressure with combined sales of Yescarta/Tecartus incrementally underperforming estimates.
Diversification ChallengesThe path to diversification outside virology has been challenging and the missteps so far have been keeping some investors on the sidelines.
Policy ChangesPotential policy changes regarding Medicaid budgets that impact HIV therapies are considered a significant risk to the company's outlook.
---
Options Prices
Currently, No data available
---
Ownership Overview
0.08% Insiders
30.41% Mutual Funds
0.26% Other Institutional Investors
42.65% Public Companies and Individual Investors
1GILD FAQ
What was Gilead Sciences’s price range in the past 12 months?
Gilead Sciences lowest stock price was €57.73 and its highest was €92.68 in the past 12 months.
What is Gilead Sciences’s market cap?
Gilead Sciences’s market cap is $109.29B.
When is Gilead Sciences’s upcoming earnings report date?
Gilead Sciences’s upcoming earnings report date is Feb 11, 2025 which is in 27 days.
How were Gilead Sciences’s earnings last quarter?
Gilead Sciences released its earnings results on Nov 06, 2024. The company reported €1.971 earnings per share for the quarter, beating the consensus estimate of €1.493 by €0.478.
Is Gilead Sciences overvalued?
According to Wall Street analysts Gilead Sciences’s price is currently Undervalued.
Does Gilead Sciences pay dividends?
Gilead Sciences pays a N/A dividend of €2.986 which represents an annual dividend yield of 3.43%. See more information on Gilead Sciences dividends here
What is Gilead Sciences’s EPS estimate?
Gilead Sciences’s EPS estimate is 1.66.
How many shares outstanding does Gilead Sciences have?
Gilead Sciences has 1,246,265,900 shares outstanding.
What happened to Gilead Sciences’s price movement after its last earnings report?
Gilead Sciences reported an EPS of €1.971 in its last earnings report, beating expectations of €1.493. Following the earnings report the stock price went up 5.454%.
Which hedge fund is a major shareholder of Gilead Sciences?
Currently, no hedge funds are holding shares in IT:1GILD
---
Gilead Sciences Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
€96.88 (9.24% Upside)
€96.88 (9.24% Upside)
Blogger Sentiment
Bullish
IT:1GILD Sentiment 100%
Sector Average 71%
Sector Average 71%
Insider Transactions
Sold Shares
Worth $15.7M over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
8.37%
12-Months-Change
Fundamentals
Return on Equity
0.62%
Trailing 12-Months
Asset Growth
-12.58%
Trailing 12-Months
Company Description
Gilead Sciences
Founded in 1987, California-based Gilead Sciences, Inc. is a biopharmaceutical company, which focuses on the research, development, and commercialization of antiviral drugs used in the treatment of diseases like human immunodeficiency virus (HIV), hepatitis B, hepatitis C, and influenza, including Harvoni and Sovaldi. It offers its products under brands including Harvoni, Genvoya, Epclusa, Truvada, Atripla, Descovy, Stribild, Viread, Odefsey, Complera/Eviplera, Sovaldi, and Vosevi.
---
1GILD Company Deck
---
1GILD Earnings Call
Q3 2024
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call presented a generally positive outlook with strong revenue growth across key segments like HIV and oncology. The company showed progress in its pipeline with promising drug candidates and improved financial guidance for 2024. However, there were challenges in the cell therapy segment and a significant impairment charge impacting financial results.Read More>---
1GILD Revenue Breakdown
67.03% HIV
8.05% Veklury
6.89% Cell Therapy
6.52% HCV
11.51% Other
---
1GILD Stock 12 Month Forecast
Average Price Target
€96.88
▲(9.24% Upside)
Technical Analysis
Gilead Sciences
―
Amgen
―
Bristol-Myers Squibb
―
Vertex Pharmaceuticals
―
Regeneron
―
Incyte
―
Merck & Company
―
Best Analysts Covering 1GILD
1 Year
1 Year Success Rate
40/63 ratings generated profit
1 Year Average Return
+9.70%
assigned a buy rating last month
Copying Salim Syed's trades and holding each position for 1 Year would result in 63.49% of your transactions generating a profit, with an average return of +9.70% per trade.
---